RNActive
RNActive is a private Tübingen-based biopharmaceutical company founded in 2000, employing 251-500 people to conduct academic research and develop RNA-based medicines, with technology aligned to CureVac's RNA platform.
- Company typePublic
- Founded2008
- HeadquartersTübingen, Germany
- Headcount251–500
- GTM typeB2B
- OfferingServices
What RNActive does
RNActive is a private for-profit biopharmaceutical company headquartered in Tübingen, Germany, founded in 2000. The firm is described as providing academic research and specialized development for RNA-based medicines, with a workforce of 251-500 employees. Its web presence is associated with CureVac's RNA platform under the URL curevac.com/rna-platform/rnactiver/, suggesting the RNActive technology is positioned within or aligned to CureVac's broader RNA technology offering.
The company's core activity centers on the research and development of RNA-based therapeutics, operating within the broader RNA medicines landscape alongside peers such as CureVac and BioNTech. The Tübingen location places RNActive within a recognized German biopharma and academic research cluster. The firmographic emphasis on "academic research" alongside medicines development implies a model that combines research services or academic collaboration with internal therapeutic pipeline development.
No specific products, clinical pipeline data, revenue figures, or partnership details were disclosed for RNActive in the available input. The company's go-to-market mechanics, pricing, and customer composition are not documented, limiting visibility into commercial operations. Data points aggregated under the RNActive company label in the input predominantly describe BioNTech (founded 2008, NASDAQ: BNTX, Cambridge MA) and are not applied to RNActive's description here.
RNActive firmographics
Firmographics- Name
- RNActive
- Legal name
- BioNTech SE
- Website
- https://curevac.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- RNActive is a private Tübingen-based biopharmaceutical company founded in 2000, employing 251-500 people to conduct academic research and develop RNA-based medicines, with technology aligned to CureVac's RNA platform.
- Ownership category
- akta.pro rank
RNActive industry classification
Industry- Product category
- RNA Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- akta.pro primary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
- akta.pro secondary industries
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)
Keywords
Where RNActive is headquartered
LocationHeadquarters
- HQ city
- Tübingen
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
RNActive business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Products and Vaccines: Revenue from approved pharmaceutical products including COVID-19 vaccines and pipeline therapeutic products for cancer and infectious diseases. Products are distributed through healthcare systems, hospitals, clinics, and pharmacies globally.
- Clinical Development and Licensing: Revenue from clinical development partnerships, licensing agreements, and co-development collaborations for pipeline candidates across oncology and infectious disease programs.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
RNActive product offering
Product offeringCore offering
RNActive is a biopharmaceutical company providing academic research and specialized development for RNA-based medicines. The company operates in Tübingen, Germany and focuses on advancing RNA-based therapeutic platforms and the development of novel medicines built on RNA biology expertise.
Product overview
BioNTech operates a diversified immunotherapy platform consisting of three complementary therapeutic modalities: mRNA cancer immunotherapies (individualized and shared neoantigen approaches), next-generation immunomodulators (including BNT327 bispecific antibody), and targeted therapies. The company executes a combination strategy aiming to develop new therapies based on synergistic modalities for cancer treatment across the continuum from adjuvant to advanced/metastatic settings. Additionally, the platform extends to infectious disease vaccines leveraging mRNA technology.
Differentiator
Problem solved
Functional benefit
Brands
- BNT327: Next-generation bispecific antibody candidate that binds to both PD-L1 and VEGF-A, acting on two validated biological mechanisms against cancer in a synergistic manner.
Quantifiable outcome
- €2.10 billion invested in R&D in 2025 for cancer care across high-incidence indications
- +2 more outcomes
Companies that use RNActive
Customer profileSegments3 records
Ideal customer profiles1 record
RNActive technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RNActive partnerships and signals
Strategic signalScale indicators4 records
Expansion highlights2 records
RNActive competitors and assessment
Company assessmentDirect peers
- Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines and siRNA therapeutics company with a comparable platform-based business model and similar indication breadth in vaccines and rare disease.
- BioNTech: BioNTech is a German-headquartered mRNA therapeutics and immunotherapy company. It is directly comparable to RNActive on modality, geography, and pipeline focus in mRNA cancer immunotherapies and infectious disease vaccines.
- Translate Bio (Pfizer): Translate Bio develops mRNA therapeutics for diseases of the lung and liver and is now part of Pfizer. It is comparable to RNActive as an mRNA platform company developing nucleic-acid-based medicines.
- Ethris: Ethris is a Munich-based mRNA therapeutics company focused on pulmonary and respiratory indications using stabilized non-immunogenic mRNA. It is directly comparable as a European-headquartered mRNA platform peer.
- Moderna: Moderna is a leading mRNA therapeutics company developing vaccines and therapeutics across infectious disease, oncology, and rare diseases. It is directly comparable to RNActive as a modality-aligned mRNA platform company competing in the same technology category.
Emerging players
- Kernal Biologics: Kernal Biologics is an mRNA therapeutics company focused on cancer immunotherapy and is comparable to RNActive as an emerging mRNA oncology platform with narrower commercial scale.
- Pantherna Therapeutics: Pantherna Therapeutics is a German mRNA therapeutics company focused on regenerative medicine and tissue-specific mRNA delivery, comparable as a European early-stage mRNA platform peer.
- Tiba Biotech: Tiba Biotech is an RNA therapeutics company developing engineered RNAi and mRNA delivery technologies for infectious disease and oncology, comparable as an emerging RNA platform peer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
RNActive social profiles
Digital presenceRNActive financial estimates
Financial estimateRevenue estimate
Valuation estimate
RNActive leadership team
Management profileNumber of profiles
RNActive funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RNActive M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RNActive
What does RNActive do?
RNActive is a biopharmaceutical company providing academic research and specialized development for RNA-based medicines. The company operates in Tübingen, Germany and focuses on advancing RNA-based therapeutic platforms and the development of novel medicines built on RNA biology expertise.
Is RNActive a public or private company?
RNActive is a public company. It is classified as corporate owned and is currently operating.
When was RNActive founded?
RNActive was founded in 2008. It employs 251 to 500 people.
Where is RNActive based?
RNActive is headquartered in Tübingen, Germany, in the Europe region.
How does RNActive make money?
Two revenue lines are on record. Pharmaceutical Products and Vaccines are the primary driver. The others are clinical Development and Licensing.
Who are RNActive's main competitors?
Direct peers on record are Arcturus Therapeutics, BioNTech, Translate Bio (Pfizer), Ethris and Moderna. Emerging players are Kernal Biologics, Pantherna Therapeutics and Tiba Biotech.
Does RNActive have an API?
No public API is recorded for RNActive.
What industry is RNActive in?
RNActive's product category is RNA Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714.